Survodutide vs Tirzepatide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicSurvodutideTirzepatide
What it is

An investigational glucagon receptor and GLP-1 receptor dual agonist from Boehringer Ingelheim, also known as BI 456906.1,7

A GIP receptor and GLP-1 receptor agonist. The Zepbound label states that it selectively binds to and activates both receptors.4

FDA status

In clinical trials

In clinical trials; not FDA-approved1,2,3

Not FDA-approved. FDA lists survodutide among unapproved drugs it has warned companies for selling with false research-use labels.3

Is survodutide FDA-approved?

FDA-approved

FDA-approved as Mounjaro and Zepbound4,5,6

FDA-approved. Drugs@FDA lists Mounjaro (first approved May 13, 2022) and Zepbound (November 8, 2023). The Zepbound label carries a boxed warning about thyroid C-cell tumors seen in rats.4,5,6

Is tirzepatide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.8

Not among the six peptides the policy lists.8

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial SYNCHRONIZE-1, a 76-week blinded, randomized, placebo-controlled Phase 3 trial in 725 adults with obesity, or overweight with a related condition, that excluded diabetes, published in The New England Journal of Medicine.9
  • Large randomized human trial A 46-week randomized, double-blind, placebo-controlled Phase 2 trial that treated 386 adults with overweight or obesity without diabetes, published in The Lancet Diabetes & Endocrinology.7
  • Controlled human trial A 48-week randomized, placebo-controlled Phase 2 trial that treated 293 adults with biopsy-confirmed MASH and liver fibrosis, published in The New England Journal of Medicine.10
  • Controlled human trial SYNCHRONIZE-MASLD, a 48-week blinded, randomized, placebo-controlled Phase 3 trial in 216 treated adults with obesity and fatty liver disease, published in Nature Medicine.11
  • Registered trial without results SYNCHRONIZE-CVOT (NCT06077864), a Phase 3 cardiovascular safety trial in people with overweight or obesity, listed as completed in its August 11, 2026 registry record. Its results are not part of the sources cited here.12

Large randomized human trials

  • Large randomized human trial A 72-week randomized, double-blind, placebo-controlled weight trial (NCT04184622) that enrolled 2,539 adults with obesity, or overweight with a weight-related condition, and excluded type 2 diabetes.4
  • Large randomized human trial A 72-week randomized, double-blind, placebo-controlled weight trial (NCT04657003) in 938 adults with type 2 diabetes and overweight or obesity.4
  • Controlled human trial Two 52-week randomized, double-blind, placebo-controlled sleep apnea trials (NCT05412004) that together enrolled 469 adults with obesity.4
  • Large randomized human trial SURPASS-CVOT, which compared tirzepatide with dulaglutide on major adverse cardiovascular events in people with type 2 diabetes. FDA’s August 2026 letter cites it as the basis for the new Mounjaro indication.13,14
Records collected

13 ClinicalTrials.gov records and 4 PubMed records collected

108 ClinicalTrials.gov records and 75 PubMed records collected

Area of study

Metabolic and weight, Liver1

Metabolic and weight4

Latest dated events
  1. FDA’s page on unapproved GLP-1 drugs, which names survodutide among drugs sold with false research-use labels, is updated, as shown by its content-current date.3
  2. Results of the Phase 3 trials SYNCHRONIZE-1 and SYNCHRONIZE-MASLD are published.9,11
  3. Results of Phase 2 trials in obesity and in MASH with fibrosis are published.7,10
  1. FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.3
  2. DailyMed publishes the Zepbound label version cited on this page.4
  3. FDA approves a new Mounjaro indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk.13

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver · record history version 50 · last update posted 2026-07-22 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  2. 2
    ClinicalTrials.gov record NCT07754461 · retained source version 2026-08-10:d71d6065261ae9f1c83fbc9694b2dc6cef63964c1377569876a214c0a75eb88e ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  3. 3
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    ZEPBOUND (tirzepatide) injection · SPL version 40 · published 2026-09-02 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

  5. 5
    Drugs@FDA application NDA215866 · original submission status AP · 2022-05-13 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Drugs@FDA application NDA217806 · original submission status AP · 2023-11-08 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  7. 7
    Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial (2024) · PMID 38330987 ↗

    The Lancet Diabetes & Endocrinology · Official source · Source checked November 14, 2026

  8. 8
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  9. 9
    Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1, 2026) · PMID 42253238 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  10. 10
    A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (2024) · PMID 38847460 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  11. 11
    Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial (2026) · PMID 42252333 ↗

    Nature Medicine · Official source · Source checked November 14, 2026

  12. 12
    ClinicalTrials.gov record NCT06077864 · retained source version 2026-08-11:60e24ca2b3858aa7bfd06f0e1cac79051207229d8181cdbe15a0399bddf60984 ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  13. 13
    Mounjaro (tirzepatide): NDA 215866 supplements S-044 and S-045 approval letter, August 27, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  14. 14
    Zepbound (tirzepatide): NDA 217806 supplement S-041 corrected approval letter, effective August 26, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026